Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$0.88 USD
+0.02 (1.95%)
Updated Apr 26, 2024 03:54 PM ET
After-Market: $0.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.88 USD
+0.02 (1.95%)
Updated Apr 26, 2024 03:54 PM ET
After-Market: $0.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Zacks News
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
by Zacks Equity Research
Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
Microbot Medical (MBOT) Announces Positive GLP Study Results
by Zacks Equity Research
Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.
Microbot Medical Inc. (MBOT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Microbot Medical Inc. (MBOT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Company News for Dec 28, 2021
by Zacks Equity Research
Companies in The News Are: GDDY,BBIO,UAL,MBOTSYK
Microbot Medical Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Microbot Medical.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Buy Multibagger Stocks as Odds of a Rally Are High in 2020
by Tirthankar Chakraborty
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.